Bloom Science
Bloom Science is a clinical-stage biotech company dedicated to developing innovative therapies targeting the Gut-Brain Axis for neurological and metabolic disorders. Their proprietary platform, IrisRx™, enables the development of multi-functional therapeutics from gut microbes, aiming to treat conditions such as Dravet syndrome, epilepsy, ALS, and other neurodegenerative diseases. The company focuses on creating safe, effective, first-in-class therapeutics inspired by the ketogenic diet, with a deep pipeline of programs and a strong IP portfolio. Bloom Science is committed to transforming patient lives through groundbreaking science and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Products
Oral live biotherapeutic candidate designed to mimic ketogenic diet effects
An investigational orally delivered live biotherapeutic candidate composed of rationally selected gut microbial strains designed to replicate metabolic and neurological effects of the ketogenic diet for indications including refractory epilepsies, Dravet syndrome, ALS, and obesity.
Oral live biotherapeutic candidate producing nicotinamide for ALS
An investigational orally delivered live biotherapeutic candidate developed to produce nicotinamide (a NAD+ pathway metabolite) with preclinical evidence of attenuating motor-neuron loss and improving lifespan and motor function in ALS model mice.
Oral live biotherapeutic candidate designed to mimic ketogenic diet effects
An investigational orally delivered live biotherapeutic candidate composed of rationally selected gut microbial strains designed to replicate metabolic and neurological effects of the ketogenic diet for indications including refractory epilepsies, Dravet syndrome, ALS, and obesity.
Oral live biotherapeutic candidate producing nicotinamide for ALS
An investigational orally delivered live biotherapeutic candidate developed to produce nicotinamide (a NAD+ pathway metabolite) with preclinical evidence of attenuating motor-neuron loss and improving lifespan and motor function in ALS model mice.
Services
Collaborative agreements and technology licenses with academic institutions and industry partners to co-develop microbial strain-based therapeutics and access preclinical assets.
End-to-end clinical development activities for live biotherapeutic candidates, including Phase 1 randomized MAD trials with PK/PD and biomarker endpoints and planned Phase 2 studies in target patient populations.
Collaborative agreements and technology licenses with academic institutions and industry partners to co-develop microbial strain-based therapeutics and access preclinical assets.
End-to-end clinical development activities for live biotherapeutic candidates, including Phase 1 randomized MAD trials with PK/PD and biomarker endpoints and planned Phase 2 studies in target patient populations.
Expertise Areas
- Microbiome-based therapeutic discovery
- Gut–brain axis biology
- Live biotherapeutic product (LBP) development
- Neuroscience and CNS drug development (epilepsy, Dravet syndrome, ALS)
Key Technologies
- Live biotherapeutic products (LBPs)
- Microbial strain selection and characterization
- Synthetic biology and strain engineering
- Metabolomics and targeted biomarker assays
News & Updates
Demonstrating statistically significant, durable weight loss in overweight individuals, with safety and tolerability supported for further development.
CEO Christopher Reyes will present program and clinical data for BL-001 targeting Dravet Syndrome and other DEEs.
CEO Christopher Reyes will discuss Bloom’s obesity program and clinical data.
BL-001 demonstrated a favorable safety and tolerability profile, with significant weight loss and ketogenic metabolic changes supporting further trials.
New patents cover bacterial strains and methods for treating seizures, broadening protection for BL-001.
Demonstrating statistically significant, durable weight loss in overweight individuals, with safety and tolerability supported for further development.
CEO Christopher Reyes will present program and clinical data for BL-001 targeting Dravet Syndrome and other DEEs.
CEO Christopher Reyes will discuss Bloom’s obesity program and clinical data.
BL-001 demonstrated a favorable safety and tolerability profile, with significant weight loss and ketogenic metabolic changes supporting further trials.
New patents cover bacterial strains and methods for treating seizures, broadening protection for BL-001.